MedTrace Logo

Prebiotic in Chronic Kidney Disease Patients

NCT02364869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-04-07

No results posted yet for this study

Summary

This 12-week double-blind randomized controlled clinical trial aims to investigate the effect of a prebiotic (fructooligosaccharide - FOS) on serum and urinary levels of uremic toxins (p-cresyl sulfate and indoxyl sulfate) of non-dialysis dependent CKD patients, and the impact of such intervention on cardiovascular markers, intestinal permeability, endotoxemia and inflammatory response.

Conditions

Interventions

DIETARY_SUPPLEMENT

Fructooligosaccharide

Patients will be evaluated at baseline, week 6 and 12.

DIETARY_SUPPLEMENT

Maltodextrin

Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.

Sponsors & Collaborators

  • Universidade Federal do Paraná

    collaborator OTHER

  • Pontifícia Universidade Católica do Paraná

    collaborator OTHER

  • Federal University of São Paulo

    lead OTHER

Principal Investigators

  • Lilian Cupari, PhD · Affiliate professor of Federal University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02364869 on ClinicalTrials.gov